The study failed on several counts. First IVM was administered up to 7 days after the 1st symptom and up to 10 days after a positive pcr test, (which itself is problematic.) Administration should begin in 3 to 5 days. Second the dosage was 400mg for everybody rather than dosed by weight. Third while it is recommwnded to give IVM for 5 to…
The study failed on several counts. First IVM was administered up to 7 days after the 1st symptom and up to 10 days after a positive pcr test, (which itself is problematic.) Administration should begin in 3 to 5 days. Second the dosage was 400mg for everybody rather than dosed by weight. Third while it is recommwnded to give IVM for 5 to 7 days at a minimum, they only gave it for three days. Fourth, the study only involved patients with mild symptoms meaning there was little for the drug to do since mild symptoms almost always pass. Fifth the median age of participants was 48 years, yet where IVM shows the most dramatic improvements is among older patients. In short, the study was designed to assure IVM displayed no benefit.
The study failed on several counts. First IVM was administered up to 7 days after the 1st symptom and up to 10 days after a positive pcr test, (which itself is problematic.) Administration should begin in 3 to 5 days. Second the dosage was 400mg for everybody rather than dosed by weight. Third while it is recommwnded to give IVM for 5 to 7 days at a minimum, they only gave it for three days. Fourth, the study only involved patients with mild symptoms meaning there was little for the drug to do since mild symptoms almost always pass. Fifth the median age of participants was 48 years, yet where IVM shows the most dramatic improvements is among older patients. In short, the study was designed to assure IVM displayed no benefit.